CNGB3 Achromatopsia - Healing Genes

CNGB3 Achromatopsia

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

Phase 1/2

Doctors at research centers in FL, MA, NY, OH, and OR seek pediatric patients with Achromatopsia due to specific genetic mutations in the CNGB3 gene. The drug uses a genetic editing tool, delivered only within the retina, designed to eliminate the harmful mutation in the CNGB3 gene. It uses a harmless virus that can selectively pass the corrected gene into the cells of the retina to enable cones to carry out phototransduction.

Treatment will involve a single injection surgery to the retina at the back of the eye, then follow up continues for 1 year.


  • Be 6 years of age or older
  • Meet genetic screening requirements specific to the study aim
  • Have achromatopsia confirmed by a retinal specialist (CI or PI)
  • Not be pregnant


  1. Screening before the treatment
  2. A single injection of the genetic therapy to the retina at the back of the eye
  3. Follow up for 1 year

The study has 6 U.S. locations:
VitreoRetinal Associates in Gainesville, FL, Map.
Bascom Palmer Eye Institute in Miami, FL, Map.
Massachusetts Eye and Ear Infirmary in Boston, MA, Map.
Columbia College of Physicians and Surgeons in New York, NY, Map.
Duke Eye Center, Duke University Medical Center in Durham, NC. Map.
Cincinnati Eye Institute in Cincinnati, OH, Map.
Casey Eye Institute, Oregon Health and Sciences University in Portland, OR. Map.
Jill Dolgin, PharmD  |  6178435781  |  [email protected]
Applied Genetic Technologies Corp
National Eye Institute (NEI)
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader